Ownership & classification
Founded: 2015
Ownership
STAT (also STAT News) is a US health, medicine and life-sciences news site launched on 4 November 2015 by John W. Henry, owner of The Boston Globe. It is produced by Boston Globe Media Partners and run as a separate brand. Ownership traces to John Henry, the billionaire businessman who bought the Globe in 2013.
Funding
Initially free, STAT has since built a paywalled subscription business (STAT+) alongside advertising, sponsored events and conferences, financed within the privately held Boston Globe Media group. It is a commercial, for-profit operation.
Affiliation & stance
STAT has no party, state or church ties and operates as an independent commercial newsroom focused on health and biotech, owned privately by John Henry's Boston Globe Media. Because it is privately and commercially owned with no party or government control, it is classified INDEPENDENT (matching the site's existing guess).
Editorial lean
- Our estimate
- Center
- Measured from coverage
- Centerbased on 309
76/100
Factual
73/100
Objective
440
Articles
440
reports
Factual: How accurately its articles report the facts, judged against primary sources and the cross-outlet consensus. Only articles that cite their sources are counted.
Objective: How neutral the writing is — whether reporting keeps the writer’s own preferences and opinions out of the article.
Recent coverage

Democrats settle on a message: ‘Medicare for More’
This newsletter highlights recent developments in U.S. healthcare politics, focusing on the administration of Health Secretary Robert F. Kennedy Jr. and the Democratic Party's strategic shifts. With the appointment of White House Chief of Staff Stephen Miller, a supporter of the Make American Healthcare Again (MAHA) movement, Kennedy is reportedly energized to pursue aggressive policy changes regarding vaccine schedules and food standards, despite facing an oppositional Congress and a growing measles epidemic. Concurrently, House Democrats have unified around a new messaging strategy called 'Medicare for More,' which proposes lowering the age of Medicare eligibility and expanding coverage for children through a plan dubbed 'Medikids.' This approach marks a departure from previous internal party divisions over universal healthcare models, though analysts suggest underlying ideological differences remain. The newsletter also includes brief segments on physician burnout, critiques of medical education, and an overview of the diverse landscape of China's biotechnology sector.

STAT+: Helus’ psychedelic drug improved depression in study but faces safety questions
A Phase 3 clinical trial conducted by Helus Pharma showed that its psychedelic drug candidate provided significant improvements in patients with major depressive disorder when used alongside standard antidepressants. Participants taking the drug saw a greater reduction in depression scores compared to those receiving a placebo, with statistically significant results observed at both six and 12 weeks. However, the study reported several serious adverse events, raising concerns about the drug's safety profile. These findings highlight the potential therapeutic benefits of the medication while underscoring the need for further evaluation of its risks.

STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics
The U.S. Food and Drug Administration has rejected ivonescimab, a lung cancer treatment developed by Summit Therapeutics and Akeso. In a letter to the companies, FDA regulators stated that the drug failed to demonstrate a survival benefit for patients, despite showing efficacy in slowing disease progression. The agency concluded that the lack of improved life expectancy did not justify a favorable benefit-risk profile necessary for approval. This decision represents a significant regulatory setback for Summit Therapeutics, which manages the drug's development outside of China, though industry observers had anticipated potential hurdles.

STAT+: Bladder cancer immunotherapy from CG Oncology reduced risk of tumor recurrence
A new cancer immunotherapy developed by CG Oncology has shown promising results in reducing the risk of bladder tumor recurrence by 68% compared to standard treatments. The therapy, known as cretostimogene, uses a modified common cold virus to target specific mutations in bladder cancer cells. It is administered directly into the bladder via a catheter, where the virus replicates and destroys the cancerous cells. This treatment was tested in a Phase 3 clinical trial involving 367 patients with intermediate-risk bladder cancer, a condition often treated with minimally invasive surgery followed by regular monitoring. If the cancer recurs, additional surgeries may be required, though repeated interventions can lead to loss of bladder function.

STAT+: Venture capitalist John Doerr says AI company, named for his late brother, could help fix primary care
Venture capitalist John Doerr announced the launch of Tom Health, an artificial intelligence company named in honor of his late brother, Tom. The new entity is being spun out of Lumeris, a value-based care firm founded fifteen years ago by the Doerr brothers based on medical concepts developed by Tom, who was a physician. According to Pitchbook data, Lumeris has raised over $620 million and currently employs 1,200 staff members. Doerr described his brother’s dedication to personalized healthcare and patient accessibility, noting that Tom often shared his personal mobile number with patients. The announcement highlights the integration of AI technology into primary care systems derived from established value-based care models.

STAT+: Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues
A new startup named Seawolf Therapeutics has received $100 million in funding from Versant Ventures, Eli Lilly, and other investors to address challenges in gene therapy. The company aims to deliver genes to patients without using viruses, which are commonly used but have limitations such as triggering immune responses and causing severe side effects at high doses. Sanofi has also partnered with Seawolf Therapeutics. This development highlights ongoing efforts to improve gene therapy approaches.

Opinion: STAT+: Candles and long baths can’t fix burned-out physicians
The article discusses physician burnout and the inadequacy of traditional 'self-care' solutions offered by hospitals, such as mindfulness exercises and wellness modules. The author, a former surgeon, shares her personal experience of finding relief through physical activities like hitting a baseball, which provided tangible stress relief unlike mandated wellness programs. She critiques the lack of effective support systems for physicians, emphasizing that current approaches fail to address the root causes of burnout. The piece highlights the need for more practical and meaningful interventions to support healthcare workers.

BeOne, Hengrui top list of China’s most powerful drugmakers
China's biotechnology sector is experiencing rapid growth, with companies like BeOne Medicines and Jiangsu Hengrui Pharmaceuticals emerging as major players in the global drugmaking landscape. These firms have adopted different strategies, BeOne focuses on establishing a global sales presence, while Hengrui partners with Western pharmaceutical giants. The rankings are based on market value and revenue, highlighting the increasing influence of Chinese biotech firms. Beijing has set ambitious goals to dominate the production of innovative drugs by 2030, prompting responses from Washington and the biotech industry regarding trade and investment policies.

Opinion: Medical school should start after students take the Step 1 exam
The article proposes a major restructuring of medical education in the United States by splitting it into two distinct phases. The first phase focuses on foundational preclinical sciences, culminating in the USMLE Step 1 exam, while the second phase emphasizes clinical training, professional development, and ethics. Current challenges include low attendance at in-person lectures, reliance on costly commercial study materials, and rising student debt. The authors suggest multiple pathways for students to complete the first phase, including self-directed learning, online courses, or formal master’s degrees, before applying to medical school after passing Step 1. This model aims to provide flexibility and reduce financial burdens.

After difficult two years, medical school group’s leadership isn’t letting its guard down post midterms
The Association of American Medical Colleges (AAMC) remains vigilant about ongoing challenges in healthcare and science policy, even after Democrats gained control of Congress. At their recent annual meeting, AAMC leaders emphasized that critical issues such as NIH funding, Medicaid cuts, and visa restrictions for international medical professionals remain unresolved. Despite a shift in political power, AAMC's Chief Public Policy Officer warned that these issues will not disappear. AAMC CEO David Skorton highlighted concerns over medical mistrust, noting that public skepticism stems from past experiences with untrustworthy institutions. He expressed hope that bipartisan support for biomedical research would continue, though he acknowledged the uncertainty brought by shifting political dynamics.

Apple launches new app to study how people use AI for health
Apple has launched a new app to study how people use AI for health-related inquiries. The app, developed in partnership with healthcare-focused AI company OpenEvidence, invites U.S. users aged 21 and older with newer iPhones to participate in a 12-month study involving up to 200,000 participants. Users can ask health-related questions and receive answers grounded in clinical data from reputable journals. They can rate these answers, provide feedback, and share health data from Apple's HealthKit for more personalized insights. Apple emphasized that all data would be anonymized and not used to train AI models, with OpenEvidence deleting query and response data within 24 hours. The goal is to understand how people interact with health AI and improve future tools.

Looming Medicaid Cuts Could End in Disaster. The Trump Administration Just Paused Them for Six Months.
The U.S. Department of Health and Human Services has announced a six-month delay before states are required to enforce new Medicaid work requirements, pushing implementation back to mid-2027. These mandates, established under the One Big Beautiful Bill Act, require able-bodied beneficiaries to document approximately 80 hours of monthly work or qualifying activity to maintain coverage. During the interim hold harmless period, states are prohibited from denying applications or disenrolling individuals solely for failing to meet these documentation standards. Critics, including Democratic lawmakers and human rights organizations, argue that the administrative burden poses significant risks to patient access to care, with estimates suggesting millions could lose coverage. The legislation was originally scheduled to take effect after the upcoming midterm elections, prompting legal challenges from multiple state attorneys general.

STAT+: Democrats coalesce around ‘Medicare for More,’ ‘Medikids’ proposals
Democratic Party members are increasingly aligning around two specific health care affordability initiatives: 'Medicare for More' and 'Medikids.' The 'Medicare for More' proposal aims to expand Medicare eligibility to additional Americans, though not necessarily to the entire population, serving as a potential compromise between the party's moderate and liberal factions. Simultaneously, the 'Medikids' plan proposes providing free health insurance to individuals from birth through age 26. These policies are described as emerging consensus positions designed to address rising cost-of-living pressures while minimizing internal party division. The article notes that these ideas are gaining traction within the party as they navigate legislative priorities.














